Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagot, Nicolas, Singata-Madliki, Mandisa, Cournil, Amandine, Nalugya, Joyce, Tassembedo, Souleymane, Quillet, Catherine, Tonga, Melany W., Tumwine, James, Meda, Nicolas, Kankasa, Chipepo, Mwiya, Mwiya, Bangirana, Paul, Peries, Marianne, Batting, Joanne, Engebretsen, Ingunn M. S., Tylleskär, Thorkild, Perre, Philippe Vande, Ndeezi, Grace, Molès, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862474/
https://www.ncbi.nlm.nih.gov/pubmed/33542437
http://dx.doi.org/10.1038/s41598-021-82762-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862474/
https://www.ncbi.nlm.nih.gov/pubmed/33542437
http://dx.doi.org/10.1038/s41598-021-82762-8

Ejemplares similares